Browse ARID1A

Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF01388 ARID/BRIGHT DNA binding domain
PF12031 SWI/SNF-like complex subunit BAF250/Osa
Function

Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity).

> Gene Ontology
 
Biological Process GO:0001654 eye development
GO:0001838 embryonic epithelial tube formation
GO:0001841 neural tube formation
GO:0001843 neural tube closure
GO:0001890 placenta development
GO:0002072 optic cup morphogenesis involved in camera-type eye development
GO:0003205 cardiac chamber development
GO:0003408 optic cup formation involved in camera-type eye development
GO:0006333 chromatin assembly or disassembly
GO:0006337 nucleosome disassembly
GO:0006338 chromatin remodeling
GO:0006342 chromatin silencing
GO:0006344 maintenance of chromatin silencing
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0009755 hormone-mediated signaling pathway
GO:0014020 primary neural tube formation
GO:0014706 striated muscle tissue development
GO:0016331 morphogenesis of embryonic epithelium
GO:0016458 gene silencing
GO:0021915 neural tube development
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030520 intracellular estrogen receptor signaling pathway
GO:0030521 androgen receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0030900 forebrain development
GO:0031076 embryonic camera-type eye development
GO:0031498 chromatin disassembly
GO:0031958 corticosteroid receptor signaling pathway
GO:0032984 macromolecular complex disassembly
GO:0032986 protein-DNA complex disassembly
GO:0034728 nucleosome organization
GO:0035051 cardiocyte differentiation
GO:0035148 tube formation
GO:0035239 tube morphogenesis
GO:0040029 regulation of gene expression, epigenetic
GO:0042692 muscle cell differentiation
GO:0042766 nucleosome mobilization
GO:0042921 glucocorticoid receptor signaling pathway
GO:0043010 camera-type eye development
GO:0043044 ATP-dependent chromatin remodeling
GO:0043241 protein complex disassembly
GO:0043401 steroid hormone mediated signaling pathway
GO:0045814 negative regulation of gene expression, epigenetic
GO:0045815 positive regulation of gene expression, epigenetic
GO:0048048 embryonic eye morphogenesis
GO:0048096 chromatin-mediated maintenance of transcription
GO:0048545 response to steroid hormone
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048592 eye morphogenesis
GO:0048593 camera-type eye morphogenesis
GO:0048596 embryonic camera-type eye morphogenesis
GO:0048608 reproductive structure development
GO:0048738 cardiac muscle tissue development
GO:0051146 striated muscle cell differentiation
GO:0055007 cardiac muscle cell differentiation
GO:0060537 muscle tissue development
GO:0060562 epithelial tube morphogenesis
GO:0060606 tube closure
GO:0060674 placenta blood vessel development
GO:0060900 embryonic camera-type eye formation
GO:0061458 reproductive system development
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071824 protein-DNA complex subunit organization
GO:0072175 epithelial tube formation
GO:0090596 sensory organ morphogenesis
GO:1901998 toxin transport
Molecular Function GO:0003682 chromatin binding
GO:0003713 transcription coactivator activity
GO:0016922 ligand-dependent nuclear receptor binding
GO:0031491 nucleosome binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0016514 SWI/SNF complex
GO:0044454 nuclear chromosome part
GO:0070603 SWI/SNF superfamily-type complex
GO:0071564 npBAF complex
GO:0071565 nBAF complex
GO:0090544 BAF-type complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-3214858: RMTs methylate histone arginines
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ARID1A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ARID1A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.74; FDR: 0.02000 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 4.02; FDR: 0.031 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ARID1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1670.443
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1160.947
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3760.775
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3540.183
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.280.923
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4470.905
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.280.481
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1990.91
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.360.856
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.670.559
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3080.432
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0030.962
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ARID1A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414257.117.90.405
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91644.412.531.90.142
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 598011.168.90.023
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.311.1-5.80.642
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.515.4-10.90.541
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARID1A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARID1A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARID1A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARID1A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ARID1A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ARID1A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolARID1A
NameAT rich interactive domain 1A (SWI-like)
Aliases B120; C10rf4; BAF250; BAF250a; C1orf4; SMARCF1; SWI/SNF related, matrix associated, actin dependent regulato ......
Chromosomal Location1p36.1-p35
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ARID1A collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.